Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-07 6:47 pm Sale |
2024-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
WASATCH ADVISORS LP | 13,993,410 6.600% |
-10,900,819 (-43.79%) |
Filing History |
| 2024-11-12 4:53 pm Unchanged |
2024-09-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 9,597,642 4.600% |
0 (Unchanged) |
Filing History |
| 2024-11-04 1:54 pm Sale |
2024-09-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 9,597,642 4.600% |
-3,001,352 (-23.82%) |
Filing History |
| 2024-08-16 6:40 pm Sale |
2024-08-14 | 13G | Sangamo Therapeutics, Inc. SGMO |
BIOGEN INC. BIIB |
3,250,000 1.600% |
-11,402,466 (-77.82%) |
Filing History |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
4,702,938 2.300% |
-9,392,927 (-66.64%) |
Filing History |
| 2024-04-05 3:59 pm Purchase |
2024-04-05 | 13G | Sangamo Therapeutics, Inc. SGMO |
WASATCH ADVISORS LP | 24,894,229 11.900% |
12,496,305 (+100.79%) |
Filing History |
| 2024-02-13 5:13 pm Sale |
2023-12-29 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 12,598,994 7.100% |
-1,446,615 (-10.30%) |
Filing History |
| 2024-02-12 7:11 pm Sale |
2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BIOGEN INC. BIIB |
14,652,466 8.260% |
-9,767,691 (-40.00%) |
Filing History |
| 2024-02-09 12:17 pm Sale |
2024-02-09 | 13G | Sangamo Therapeutics, Inc. SGMO |
WASATCH ADVISORS LP | 12,397,924 7.000% |
-5,588,857 (-31.07%) |
Filing History |
| 2024-01-26 11:49 am Sale |
2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
14,095,865 7.900% |
-1,263,576 (-8.23%) |
Filing History |
| 2024-01-22 12:18 pm Sale |
2023-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
STATE STREET CORP STT |
2,708,368 1.530% |
-7,080,516 (-72.33%) |
Filing History |
| 2023-10-10 3:09 pm Purchase |
2023-10-10 | 13G | Sangamo Therapeutics, Inc. SGMO |
WASATCH ADVISORS LP | 17,986,781 10.160% |
5,336,027 (+42.18%) |
Filing History |
| 2023-02-09 4:21 pm Purchase |
2023-02-09 | 13G | Sangamo Therapeutics, Inc. SGMO |
WASATCH ADVISORS LP | 12,650,754 7.700% |
1,689,772 (+15.42%) |
Filing History |
| 2023-02-09 11:32 am Purchase |
2022-12-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 14,045,609 8.570% |
4,705,054 (+50.37%) |
Filing History |
| 2023-02-07 1:49 pm Purchase |
2022-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
STATE STREET CORP STT |
9,788,884 5.970% |
4,974,258 (+103.32%) |
Filing History |
| 2023-01-24 1:56 pm Purchase |
2022-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
15,359,441 9.400% |
3,696,561 (+31.70%) |
Filing History |
| 2022-02-10 5:42 pm Purchase |
2022-02-11 | 13G | Sangamo Therapeutics, Inc. SGMO |
WASATCH ADVISORS LP | 10,960,982 7.500% |
888,601 (+8.82%) |
Filing History |
| 2022-02-10 08:37 am Purchase |
2021-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 9,340,555 6.410% |
886,897 (+10.49%) |
Filing History |
| 2022-02-01 5:08 pm Purchase |
2021-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
BlackRock Inc. BLK |
11,662,880 8.000% |
2,096,465 (+21.91%) |
Filing History |
| 2021-02-11 2:09 pm Purchase |
2021-02-11 | 13G | Sangamo Therapeutics, Inc. SGMO |
WASATCH ADVISORS LP | 10,072,381 7.100% |
2,585,364 (+34.53%) |
Filing History |